Treatment algorithm for the management of hepatitis C in HIV-coinfected persons

被引:14
作者
Sulkowski, MS [1 ]
机构
[1] Johns Hopkins Med Inst, Baltimore, MD 21287 USA
关键词
HCV; HIV; peginterferon; ribavirin;
D O I
10.1016/j.jhep.2005.11.012
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
In the era of highly effective antiretroviral therapy (ART), HCV-related liver disease has emerged as a significant cause of morbidity and mortality. Accordingly, expert panels have recommend that coinfected patients undergo medical evaluation for HCV-related liver disease, consideration for HCV treatment and, if indicated, orthotopic liver transplantation. While the treatment of such patients is complicated by medical, and psychiatric comorbidities, HIV disease, and concurrent antiretroviral therapy, randomized controlled trials support the safety, tolerability and efficacy of HCV treatment with peginterferon alfa (PEG-IFN) plus ribavirin (RBV) in HIV-infected persons. Although, the available data has led to consensus among experts regarding the need to medically manage HCV disease in HIV-infected persons, uncertainty remains regarding the best treatment algorithm for coinfected patients. (c) 2005 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:S49 / S55
页数:7
相关论文
共 37 条
[1]  
Tablan Ofelia C, 2004, MMWR Recomm Rep, V53, P1
[2]  
[Anonymous], 1998, MMWR-MORBID MORTAL W, V47, P1
[3]  
[Anonymous], 1999, MMWR, V48, DOI [DOI 10.1037/E547822006-001, 10.1037/e547822006-001]
[4]   RIBAVIRIN ANTAGONIZES INHIBITORY EFFECTS OF PYRIMIDINE 2',3'-DIDEOXYNUCLEOSIDES BUT ENHANCES INHIBITORY EFFECTS OF PURINE 2',3'-DIDEOXYNUCLEOSIDES ON REPLICATION OF HUMAN-IMMUNODEFICIENCY-VIRUS INVITRO [J].
BABA, M ;
PAUWELS, R ;
BALZARINI, J ;
HERDEWIJN, P ;
DECLERCQ, E ;
DESMYTER, J .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) :1613-1617
[5]   Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection [J].
Bica, I ;
McGovern, B ;
Dhar, R ;
Stone, D ;
McGowan, K ;
Scheib, R ;
Snydman, DR .
CLINICAL INFECTIOUS DISEASES, 2001, 32 (03) :492-497
[6]   Treatment of chronic hepatitis C in HIV/HCV-coinfection with interferon α-2b+ full-course vs 16-week delayed ribavirin [J].
Bräu, N ;
Rodriguez-Torres, M ;
Prokupek, D ;
Bonacini, M ;
Giffen, CA ;
Smith, JJ ;
Frost, KR ;
Kostman, JR .
HEPATOLOGY, 2004, 39 (04) :989-998
[7]   Current concepts: Liver biopsy. [J].
Bravo, AA ;
Sheth, SG ;
Chopra, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (07) :495-500
[8]   Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial [J].
Carrat, F ;
Bani-Sadr, F ;
Pol, S ;
Rosenthal, E ;
Lunel-Fabiani, F ;
Benzekri, A ;
Morand, P ;
Goujard, C ;
Pialoux, G ;
Piroth, L ;
Salmon-Céron, D ;
Degott, C ;
Cacoub, P ;
Perronne, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2004, 292 (23) :2839-2848
[9]   Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons [J].
Chung, RT ;
Andersen, J ;
Volberding, P ;
Robbins, GK ;
Liu, T ;
Sherman, KE ;
Peters, MG ;
Koziel, MJ ;
Bhan, AK ;
Alston, B ;
Colquhoun, D ;
Nevin, T ;
Harb, G ;
van der Horst, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (05) :451-459
[10]  
DHHS, 2004, GUID US ANT AG HIV I